CPRX (Catalyst Pharmaceuticals) Cyclically Adjusted Book per Share: $2.83 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPRX Catalyst Pharmaceuticals Inc CPRX
70 GF Score
Price $31.49
GF Value $25.01
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Cyclically Adjusted Book per Share?

Catalyst Pharmaceuticals CPRX +0.02% 70 Cyclically Adjusted Book per Share is $2.83 as of Mar. 2026. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.01 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $8.288. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.83 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Catalyst Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 35.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 34.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 33.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Catalyst Pharmaceuticals was 34.00% per year. The lowest was -8.20% per year. And the median was 12.00% per year.

As of today (2026-09-02), Catalyst Pharmaceuticals's current stock price is $31.49. Catalyst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $2.83. Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 11.13.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Catalyst Pharmaceuticals was 19.49. The lowest was 4.79. And the median was 9.57.


Catalyst Pharmaceuticals  (NAS:CPRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=31.49/2.83
=11.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Catalyst Pharmaceuticals was 19.49. The lowest was 4.79. And the median was 9.57.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Catalyst Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Catalyst Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Catalyst Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals Cyclically Adjusted Book per Share Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 1.08 1.41 1.93 2.60

Catalyst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.09 2.25 2.43 2.60 2.83

CPRX vs PBLS, ELVN, RLAY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


CPRX
70GF Score
Catalyst Pharmaceuticals Inc CPRX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Catalyst Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.288/330.2130*330.2130
=8.288

Current CPI (Mar. 2026) = 330.2130.

Catalyst Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.559 241.018 0.766
201609 0.518 241.428 0.708
201612 0.474 241.432 0.648
201703 0.423 243.801 0.573
201706 0.402 244.955 0.542
201709 0.372 246.819 0.498
201712 0.790 246.524 1.058
201803 0.743 249.554 0.983
201806 0.693 251.989 0.908
201809 0.624 252.439 0.816
201812 0.494 251.233 0.649
201903 0.498 254.202 0.647
201906 0.615 256.143 0.793
201909 0.757 256.759 0.974
201912 0.848 256.974 1.090
202003 0.964 258.115 1.233
202006 1.075 257.797 1.377
202009 1.511 260.280 1.917
202012 1.634 260.474 2.071
202103 1.721 264.877 2.146
202106 1.832 271.696 2.227
202109 1.926 274.310 2.319
202112 2.008 278.802 2.378
202203 2.139 287.504 2.457
202206 2.347 296.311 2.616
202209 2.595 296.808 2.887
202212 2.854 296.797 3.175
202303 3.150 301.836 3.446
202306 3.524 305.109 3.814
202309 3.270 307.789 3.508
202312 3.621 306.746 3.898
202403 4.757 312.332 5.029
202406 5.135 314.175 5.397
202409 5.542 315.301 5.804
202412 6.020 315.605 6.299
202503 6.513 319.799 6.725
202506 6.994 322.561 7.160
202509 7.466 324.800 7.590
202512 7.789 324.054 7.937
202603 8.288 330.213 8.288

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $2.83 mean?
Catalyst Pharmaceuticals (CPRX) has a Cyclically Adjusted Book per Share of $2.83 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Catalyst Pharmaceuticals' current Cyclically Adjusted Book per Share is $2.83. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Cyclically Adjusted Book per Share compare to PBLS and ELVN?
Catalyst Pharmaceuticals' Cyclically Adjusted Book per Share of $2.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current Cyclically Adjusted Book per Share is $2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is $2.83. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current Cyclically Adjusted Book per Share is $2.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01. GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for CPRX:

  • Cyclically Adjusted Book per Share: $2.83
  • GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Catalyst Pharmaceuticals Business Description

Other Exchanges CN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score

Get the complete analysis for CPRX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.49
Price
$25.01
GF Value